Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio (PASG) announced new interim results from the first six patients in its Phase 1/2 study for PBGM01 targeted at GM1 Gangliosidosis ((GM1)), Read full story here.

Fintel reports that on September 3, 2024, Rodman & Renshaw initiated coverage of Passage Bio (NasdaqGS:PASG) with a Buy recommendation. Analyst Price Forecast Suggests 940.03% Upside As of August ...

For PASG, shares are up 24.26% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 3.78% over the same time period.

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...